Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

ARCH PATHOL LAB MED：使用当前和近期分类的非小细胞肺癌的病理学家间诊断协议

2018-12-29 MedSci MedSci原创

非小细胞肺癌
关注

病理学家诊断协议（IPDA）的测量应该允许病理学家改进当前的诊断标准和疾病分类。本研究通过最近的NSCLC重新分类，确定如何通过向苏木精 - 伊红（H＆E）添加一组粘蛋白和免疫组织化学（IHC）染色来影响病理学家诊断非小细胞肺癌（NSCLC）的IPDA。 基于网络的调查，研究人员向22名执业病理学家提供54个NSCLC病例的核心图像进行诊断，最初仅作为H＆E，然后为H＆E加粘蛋白和4个IHC

病理学家诊断协议（IPDA）的测量应该允许病理学家改进当前的诊断标准和疾病分类。本研究通过最近的NSCLC重新分类，确定如何通过向苏木精 - 伊红（H＆E）添加一组粘蛋白和免疫组织化学（IHC）染色来影响病理学家诊断非小细胞肺癌（NSCLC）的IPDA。

基于网络的调查，研究人员向22名执业病理学家提供54个NSCLC病例的核心图像进行诊断，最初仅作为H＆E，然后为H＆E加粘蛋白和4个IHC染色。每个病例均根据公布的2004,2011和2015年NSCLC分类进行诊断。针对231名病理学家对计算科恩kappa作为IPDA的衡量标准。

结果显示，22名病理学家通过使用4种已发表的分类诊断出54例NSCLC病例。H＆E /粘蛋白/ IHC诊断的IPDA明显高于H＆E诊断。H＆E /粘蛋白/ IHC诊断的IPDA在2015年分类中最高。在将所述诊断分解为小标题或二分类后，IPDA会更高。2015年世界卫生组织分类的H＆E /粘蛋白/ IHC诊断的IPDA对于社区和学术病理学家来说是相似的，并且当病理学家具有肺病理学专业知识，具有超过6年的实践经验或每年诊断超过100个新的肺癌时。

研究表明，较高的IPDA与粘蛋白和IHC染色的使用，2015年NSCLC分类，病理学家的肺病理学专业知识，实践持续时间和肺癌病例的频率有关。

原始出处：

William K. Funkhouser Jr, D. Neil Hayes, Interpathologist Diagnostic Agreement for Non–Small Cell Lung Carcinomas Using Current and Recent Classifications

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2059777, encodeId=ce3f2059e77fe, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat Jun 01 14:47:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786229, encodeId=40661e8622992, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jul 23 11:47:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473465, encodeId=fbe114e3465e5, content=<a href='/topic/show?id=4fd1e102257' target=_blank style='color:#2F92EE;'>#病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71022, encryptionId=4fd1e102257, topicName=病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ce7226273, createdName=jktdtl, createdTime=Mon Dec 31 03:47:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609439, encodeId=c09116094399e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Dec 31 03:47:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
    2019-06-01 lingaifan

    #非小细胞#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2059777, encodeId=ce3f2059e77fe, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat Jun 01 14:47:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786229, encodeId=40661e8622992, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jul 23 11:47:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473465, encodeId=fbe114e3465e5, content=<a href='/topic/show?id=4fd1e102257' target=_blank style='color:#2F92EE;'>#病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71022, encryptionId=4fd1e102257, topicName=病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ce7226273, createdName=jktdtl, createdTime=Mon Dec 31 03:47:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609439, encodeId=c09116094399e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Dec 31 03:47:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
    2019-07-23 爆笑小医

    #Pathol#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2059777, encodeId=ce3f2059e77fe, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat Jun 01 14:47:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786229, encodeId=40661e8622992, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jul 23 11:47:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473465, encodeId=fbe114e3465e5, content=<a href='/topic/show?id=4fd1e102257' target=_blank style='color:#2F92EE;'>#病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71022, encryptionId=4fd1e102257, topicName=病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ce7226273, createdName=jktdtl, createdTime=Mon Dec 31 03:47:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609439, encodeId=c09116094399e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Dec 31 03:47:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
    2018-12-31 jktdtl

    #病理学#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2059777, encodeId=ce3f2059e77fe, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Sat Jun 01 14:47:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786229, encodeId=40661e8622992, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Jul 23 11:47:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473465, encodeId=fbe114e3465e5, content=<a href='/topic/show?id=4fd1e102257' target=_blank style='color:#2F92EE;'>#病理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71022, encryptionId=4fd1e102257, topicName=病理学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ce7226273, createdName=jktdtl, createdTime=Mon Dec 31 03:47:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609439, encodeId=c09116094399e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Dec 31 03:47:00 CST 2018, time=2018-12-31, status=1, ipAttribution=)]
    2018-12-31 ms3994565386320060

    #Med#

    0

相关资讯

JCO：EGFR突变腺癌转化为非小细胞肺癌和其他神经内分泌肿瘤

大约3％至10％的EGFR突变的非小细胞肺癌（NSCLC）会转化为小细胞肺癌（SCLC），但其临床过程尚不明确。JCO近期发表了一篇文章研究这一问题。

CLIN CANCER RES：MERTK抑制剂联合EGFR TKI治疗非小细胞肺癌

肺癌是癌症相关死亡的主要原因。非小细胞肺癌（NSCLC）占所有肺癌的85％，超过60％表达野生型EGFR（wtEGFR）。然而，EGFR酪氨酸激酶抑制剂（TKIs）在大多数wtEGFR肿瘤患者中作用有限。MERTK酪氨酸激是NSCLC的潜在治疗靶点，MRX-2843是一种新型MERTK选择性抑制剂，具有良好的临床转化性。CLIN CANCER RES近期发表了一篇文章，研究MERTK和EGFR抑制

CLIN CANCER RES：Osimertinib治疗EGFR突变非小细胞肺癌的耐药机制

Osimertinib最初被批准用于治疗T790M阳性非小细胞肺癌（NSCLC），最近用于EGFR -mutant NSCLC的一线治疗。但是osimertinib的耐药机制尚不完全清楚。CLIN CANCER RES近期发表了一篇文章研究这一问题。

NEJM：Durvalumab可显著延长III期无法切除的非小细胞肺癌患者总生存期

Durvalumab可显著延长III期无法切除的非小细胞肺癌患者总生存期

欧盟委员会批准ALUNBRIG（brigatinib）治疗ALK+非小细胞肺癌

武田制药近日宣布，欧盟委员会已经批准ALUNBRIG（brigatinib）上市，单药治疗先前经克唑替尼治疗的成人间变性淋巴瘤激酶阳性（ALK+）的晚期非小细胞肺癌患者（NSCLC）。该决定遵循了2018年9月20日人用药品委员会（CHMP）的积极意见。

JCO：EGFR突变非小细胞肺癌患者接受厄洛替尼辅助治疗可以改善预后

表皮生长因子受体（EGFR）抑制剂在晚期EGFR突变非小细胞肺癌（NSCLC）治疗中具有关键作用，JCO近期发表了一篇文章，研究EGFR突变的早期NSCLC 患者接受辅助厄洛替尼治疗的效果。

Baidu
map
Baidu
map
Baidu
map